Study S001650

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Different Titration Schedules of Subcutaneous Doses of BI 1820237 Alone or Together With Either Semaglutide or BI 456906 in Otherwise Healthy Male and Female Individuals With Obesity/Overweight (Multiple Dose, Single-blind, Randomised, Placebo-controlled, Parallel Group Design)

ClinicalTrials.gov record

Registration

Registration: NCT05751226
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: SINGLE
Status: COMPLETED
Enrollment: 88
Start: 2023-04-11
Primary completion: 2024-08-01
Lead sponsor: Boehringer Ingelheim
Conditions: Healthy; Obesity
Interventions: DRUG:BI 1820237; DRUG:semaglutide; DRUG:Placebo; DRUG:BI 456906
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: EUDRACT_NUMBER:2022-002733-34

Registered primary outcomes

Percentage of treatment-emergent adverse events [Up to 180 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.